Cargando…

Lipid Testing and Statin Dosing After Acute Myocardial Infarction

BACKGROUND: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines recommend high‐intensity statins for patients after myocardial infarction (MI) rather than treating to a low‐density lipoprotein cholesterol goal, as the previous ATP III (Adult Treatment Panel thir...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, William T., Hellkamp, Anne, Doll, Jacob A., Thomas, Laine, Navar, Ann Marie, Fonarow, Gregg C., Julien, Howard M., Peterson, Eric D., Wang, Tracy Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850230/
https://www.ncbi.nlm.nih.gov/pubmed/29371200
http://dx.doi.org/10.1161/JAHA.117.006460
_version_ 1783306195800424448
author Wang, William T.
Hellkamp, Anne
Doll, Jacob A.
Thomas, Laine
Navar, Ann Marie
Fonarow, Gregg C.
Julien, Howard M.
Peterson, Eric D.
Wang, Tracy Y.
author_facet Wang, William T.
Hellkamp, Anne
Doll, Jacob A.
Thomas, Laine
Navar, Ann Marie
Fonarow, Gregg C.
Julien, Howard M.
Peterson, Eric D.
Wang, Tracy Y.
author_sort Wang, William T.
collection PubMed
description BACKGROUND: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines recommend high‐intensity statins for patients after myocardial infarction (MI) rather than treating to a low‐density lipoprotein cholesterol goal, as the previous ATP III (Adult Treatment Panel third report) guidelines had advised. METHODS AND RESULTS: To evaluate the frequency of postdischarge lipid testing and high‐intensity statin use among MI patients discharged on a statin during the ATP III guidelines era, we linked ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry data to Medicare claims for 11 046 MI patients aged ≥65 years who were discharged alive on a statin from 347 hospitals (2007–2009). Multivariable regression was used to evaluate the association between lipid testing and 1‐year high‐intensity statin use. Only 21% of MI patients were discharged on a high‐intensity statin. By 90 days after MI, 44% of patients discharged on a statin underwent lipid testing (43% on low‐ or moderate‐intensity statins and 49% on high‐intensity statins; P=0.001). Follow‐up lipid testing rates were 47% among patients with in‐hospital low‐density lipoprotein cholesterol ≥100 mg/dL and 47% among newly prescribed statin recipients. By 1 year, only 14% of patients were on high‐intensity statins. Only 4% of patients discharged on low‐ or moderate‐dose statin were uptitrated to high intensity; postdischarge lipid testing was associated with a slightly higher likelihood of high‐intensity statin use by 1 year (5.4% versus 2.9%, adjusted odds ratio: 1.92; 95% confidence interval, 1.52–2.41). CONCLUSIONS: Previous guidelines recommended low‐density lipoprotein cholesterol goal‐directed statin therapy, but lipid testing and high‐intensity statin use were infrequent after MI. The American College of Cardiology/American Heart Association guidelines may promote more intensive cardiovascular risk reduction by eliminating treatment dependence on lipid testing.
format Online
Article
Text
id pubmed-5850230
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58502302018-03-21 Lipid Testing and Statin Dosing After Acute Myocardial Infarction Wang, William T. Hellkamp, Anne Doll, Jacob A. Thomas, Laine Navar, Ann Marie Fonarow, Gregg C. Julien, Howard M. Peterson, Eric D. Wang, Tracy Y. J Am Heart Assoc Original Research BACKGROUND: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines recommend high‐intensity statins for patients after myocardial infarction (MI) rather than treating to a low‐density lipoprotein cholesterol goal, as the previous ATP III (Adult Treatment Panel third report) guidelines had advised. METHODS AND RESULTS: To evaluate the frequency of postdischarge lipid testing and high‐intensity statin use among MI patients discharged on a statin during the ATP III guidelines era, we linked ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry data to Medicare claims for 11 046 MI patients aged ≥65 years who were discharged alive on a statin from 347 hospitals (2007–2009). Multivariable regression was used to evaluate the association between lipid testing and 1‐year high‐intensity statin use. Only 21% of MI patients were discharged on a high‐intensity statin. By 90 days after MI, 44% of patients discharged on a statin underwent lipid testing (43% on low‐ or moderate‐intensity statins and 49% on high‐intensity statins; P=0.001). Follow‐up lipid testing rates were 47% among patients with in‐hospital low‐density lipoprotein cholesterol ≥100 mg/dL and 47% among newly prescribed statin recipients. By 1 year, only 14% of patients were on high‐intensity statins. Only 4% of patients discharged on low‐ or moderate‐dose statin were uptitrated to high intensity; postdischarge lipid testing was associated with a slightly higher likelihood of high‐intensity statin use by 1 year (5.4% versus 2.9%, adjusted odds ratio: 1.92; 95% confidence interval, 1.52–2.41). CONCLUSIONS: Previous guidelines recommended low‐density lipoprotein cholesterol goal‐directed statin therapy, but lipid testing and high‐intensity statin use were infrequent after MI. The American College of Cardiology/American Heart Association guidelines may promote more intensive cardiovascular risk reduction by eliminating treatment dependence on lipid testing. John Wiley and Sons Inc. 2018-01-25 /pmc/articles/PMC5850230/ /pubmed/29371200 http://dx.doi.org/10.1161/JAHA.117.006460 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Wang, William T.
Hellkamp, Anne
Doll, Jacob A.
Thomas, Laine
Navar, Ann Marie
Fonarow, Gregg C.
Julien, Howard M.
Peterson, Eric D.
Wang, Tracy Y.
Lipid Testing and Statin Dosing After Acute Myocardial Infarction
title Lipid Testing and Statin Dosing After Acute Myocardial Infarction
title_full Lipid Testing and Statin Dosing After Acute Myocardial Infarction
title_fullStr Lipid Testing and Statin Dosing After Acute Myocardial Infarction
title_full_unstemmed Lipid Testing and Statin Dosing After Acute Myocardial Infarction
title_short Lipid Testing and Statin Dosing After Acute Myocardial Infarction
title_sort lipid testing and statin dosing after acute myocardial infarction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850230/
https://www.ncbi.nlm.nih.gov/pubmed/29371200
http://dx.doi.org/10.1161/JAHA.117.006460
work_keys_str_mv AT wangwilliamt lipidtestingandstatindosingafteracutemyocardialinfarction
AT hellkampanne lipidtestingandstatindosingafteracutemyocardialinfarction
AT dolljacoba lipidtestingandstatindosingafteracutemyocardialinfarction
AT thomaslaine lipidtestingandstatindosingafteracutemyocardialinfarction
AT navarannmarie lipidtestingandstatindosingafteracutemyocardialinfarction
AT fonarowgreggc lipidtestingandstatindosingafteracutemyocardialinfarction
AT julienhowardm lipidtestingandstatindosingafteracutemyocardialinfarction
AT petersonericd lipidtestingandstatindosingafteracutemyocardialinfarction
AT wangtracyy lipidtestingandstatindosingafteracutemyocardialinfarction